Navigation Links
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Date:11/19/2007

hrough paper in Science magazine (Science. 1999 Sep 10;285). Using RNA interference technology to temporarily inhibit p53 in acute settings such as acute kidney injury, apoptosis is delayed thereby allowing natural repair mechanisms to restore normal DNA and cellular integrity.

About Acute Renal Failure (ARF) / Acute Kidney Injury (AKI)

ARF is a syndrome characterized by a rapid decline of kidney function leading to death in a high percentage of cases. Major cardiac surgery is one of the many causes of ARF. During cardiac bypass surgery, lack of oxygen caused by reduced local blood flow to the kidneys, followed by rapid reintroduction of oxygen, or reperfusion, to the kidneys upon removal of the patient from cardiopulmonary bypass, initiates a chain of events that can lead to ARF. Currently, there are no approved drug therapies that effectively prevent or treat ARF.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company focused on discovering and developing novel therapeutics based on its proprietary gene discovery science and technology, with an initial focus on drug candidates that work through the natural mechanism in the cell known as RNA interference, or RNAi, for the treatment of diseases associated with oxidative stress. Quark believes that its proprietary target gene discovery platform, BiFARTM, combined with its ability to design and successfully deliver synthetic molecules of the new class of RNAi therapeutics known as small-interfering RNA, or siRNA, to specific organs in the body, enables the Company to rapidly develop drug candidates. Quark has two internally discovered and developed clinical stage lead product candidates: RTP801i-14 in phase I/IIa clinical trial for the treatment of wet age-related macular degeneration, and AKIi-5 in phase I for the prevention of acute renal failure both of which have an AtuRNAi technology-based structure licensed from Silence Therapeutics, as
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...SALT LAKE CITY, Dec. 4 D...it has signed a sole-source vendor agreement to pr...hmark Physical Therapy with 65 clinics located in ...e named the sole-source supplier to Benchmark Phys...ice president of sales and marketing at Dynatronic...
(Date:12/4/2009)..., , LAKE FOREST, Ill., Dec. 4 /PRNewswi...eading global specialty pharmaceutical and medicat...f its next-generation 50 mL and 100 mL VisIV(TM) c...olutions, and now offers a complete size range (50...responsible VisIV product. The launch of the 50 mL...
(Date:12/4/2009)..., BILLERICA, Mass., Dec. 4 /PRNewswire-FirstCall...idiary of Volcano Corporation (Nasdaq: VOLC ), to...ul testing of a novel integrated light source arch...prietary optical engine design raises the bar on i... of laser-based designs for swept source OCT light...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 1Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 3Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 4Unique Facility Designed for the Comfort of Hospice Patients and Their Families 49585 1Unique Facility Designed for the Comfort of Hospice Patients and Their Families 49585 2Unique Facility Designed for the Comfort of Hospice Patients and Their Families 49585 3BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 1BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 2BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 3
...ASHVILLE, Tenn., Feb. 25 After all standard treat...ed the growth of aggressive sarcomas in two recent...otocol,s previous success against several cancers,...ma and other sarcomas. , , One of the patients is...a (MFH) that arose in the largest bone of his leg....
...rimate trials validate efficacy of the process , ...Inc. announced today that it has successfully comp...ficacy of the proprietary bone growth regeneration... 100% fusion was obtained in a 3 month period. No...ntly preparing Pre-IDE studies. , , Bone Biologic...
Other Medicine Technology:New Cancer Treatment Stops Aggressive Sarcomas 2Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix 2
(Date:12/4/2009)... , SAN FRANCISCO, Dec. 4 Me...as the favorite dispensary in the SF Bay Area by p...weedmaps.com. Despite only three months in operat...as the preeminent location for accessing medicinal...of Medithrive confirms the obvious: a dispensary w...
(Date:12/4/2009)... , MADISON HEIGHTS, Mich., Dec. 4 /...es Review Committee of BetterInvesting Magazine ... its February 2010 "Stock to Study" and C.R. Bard...valued Stock" for investors, informational and edu...because of growth opportunities involving its flag...
(Date:12/4/2009)... , STANFORD, Calif. A new study shows that mu...ne,s ability to squeeze shut properly. The work, p...reat patients with conditions such as gastric refl...be used to strengthen sphincters, which are the ba...your intestinal tract. Weakness in these areas can...
(Date:12/4/2009)... Dental tourism is a phenome...or an alternative to the high price of dental work...search for lower priced dental care, people have f...e as a dental tourist destination. , ...g in business for more than 6 years, Mexican Denta...
(Date:12/4/2009)... , Dr. Redlener Applauds Historic Effor...y Net Programs Are Lost in Final Health Care Refor... -- The New England Journal of Medicine today ...ealth care reform, co-authored by Irwin Redlener, ...or, National Center for Disaster Preparedness and ...
Breaking Medicine News(10 mins):Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2
...d and Drug Administration have lifted a 14 year ba...s. //Allergan Inc of Irvine and Mentor Corporation... to market the implants to women over 22 years of ... of clinical data to garner support for marketing ...
...ts treated with Actonel are more likely to sustain...e published today in the peer-reviewed journal Ost... 33,000 women with osteoporosis. The study of ...(risedronate sodium) were approximately half as li...
..., announced on Thursday that he proposed to intro...laces. // The bill is better known as "Texas... restaurants and other public places would be bann... "Even though cities all over the state - includin...
... one thing – in this case, increase the heart rate... time you get a sudden jolt, adrenaline (a.k.a. ep...r. Nevin A. Lambert, a biophysicist at the Medical...ch, to be published in the Nov. 21 print issue of ...
... are affected by Obstructive Sleep Apnea (OSA) and... harmful //psychological symptoms than people with...in Journal of Forensic Sciences. Sex offender... mouth through a respiratory mask while the subjec...
...(MBL) of the University of Massachusetts Medical S...y announce //the formation of an historic collabor...tive approach for preventing rabies in people. ...U.S. Centers for Disease Control and Prevention (C...
Other Medicine News:Health News:FDA gives the green signal for silicone breast implants 2Health News:Actonel Treats Hip Fractures In A Better Way Than Alendronate 2Health News:Sticky Proteins Provide New Insight Into Drug Action 2Health News:Sticky Proteins Provide New Insight Into Drug Action 3Health News:International Collaboration Takes Aim at Rabies 2Health News:International Collaboration Takes Aim at Rabies 3
SterilGARDIII Advance; SG-603
ANALYTICAL BALANCES AW320
A&D HM-300
A&D GR-200
Medicine Products: